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PURPOSE. Diabetic retinopathy (DR) is a leading cause of visual impairment. Müller cells
in DR are dysfunctional due to downregulation of the inwardly rectifying potassium
channel Kir4.1. Metformin, a commonly used oral antidiabetic drug, is known to elicit its
action through 5′ adenosine monophosphate-activated protein kinase (AMPK), a cellular
metabolic regulator; however, its effect on Kir4.1 channels is unknown. For this study,
we hypothesized that metformin treatment would correct circadian rhythm disruption
and Kir4.1 channel dysfunction in db/db mice.
METHODS. Metformin was given orally to db/db mice. Wheel-running activity, retinal
levels of Kir4.1, and AMPK phosphorylation were determined at study termination. In
parallel, rat retinal Müller cell line (rMC-1) cells were treated using metformin and 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR) to assess the effect of AMPK acti-
vation on the Kir4.1 channel.
RESULTS. The wheel-running activity of the db/db mice was improved following the
metformin treatment. The Kir4.1 level in Müller cells was corrected after metformin treat-
ment. Metformin treatment led to an upregulation of clock regulatory genes such as
melanopsin (Opn4) and aralkylamine N-acetyltransferase (Aanat). In rMC-1 cells, AMPK
activation via AICAR and metformin resulted in increased Kir4.1 and intermediate core
clock component Bmal-1 protein expression. The silencing of Prkaa1 (gene for AMPKα1)
led to decreased Kir4.1 and Bmal-1 protein expression.
CONCLUSIONS. Our findings demonstrate that metformin corrects abnormal circadian
rhythm and Kir4.1 channels in db/db mouse a model of type 2 diabetes. Metformin
could represent a critical pharmacological agent for preventing Müller cell dysfunction
observed in human DR.
Keywords: Müller cell dysfunction, circadian rhythm, AMPK
Diabetes is a progressive metabolic disorder, advancedby complex interactions among various environmen-
tal and genetic influences. Diabetic retinopathy (DR) is
observed in one-third of the diabetic population1 and is
a major complication of diabetes, affecting visual function
and acuity.2 DR continues to be one of the major causes
of blindness, contributing to 4.8% of the visually impaired
population worldwide.3,4 The multifaceted and multifacto-
rial trait of DR is a major hurdle in developing treatments
for initial stages of DR. The progression of DR is gradually
gaining appreciation as a disease of the neurovascular unit,
and several studies propose that diabetes-induced variations
in retinal neurons and glia lead to early clinically manifested
vascular injury.5
Müller cells are the principal glial cells of the retina,
spanning and enclosing the depth of retinal neurons.6
Müller cells have an array of ion channels, ligand recep-
tors, and transmembrane transporter molecules.7 Specialized
inwardly rectifying potassium (Kir) channels regulate potas-
sium conductance in Müller cells. Kir4.1, a weak rectifying
potassium channel, is expressed predominately in Müller
cells and contributes to both inward and outward potassium
currents.8,9 Kir4.1 manifests in a polarized arrangement in
Müller cells, apparent at proximal endfoot regions, subreti-
nal spaces, and perivascular regions.6 Müller cells, in part,
maintain retinal osmoregulation, and it has been suggested
that diabetes dampens retinal Kir4.1 expression and causes
Müller cell swelling.6,7 Thus, any alteration in Kir4.1 activity
greatly disturbs the functionality of Müller cells.
Müller cells have an internal signaling pathway that
prevents osmotic swelling, and an osmotic imbalance
results in the release of adenosine triphosphate (ATP) by
Müller cells.10,11 This change is sensed by 5′ adenosine
monophosphate-activated protein kinase (AMPK), which is
activated through an increase in AMP/ATP. AMPK repre-
sents a critical cellular metabolic sensor that balances fuel
metabolism in response to energy demand and supply.12
AMPK is known to be activated by various conditions such
as hypoxia, ischemia, and glucose reduction.13
Circadian clocks synchronize with daily light/dark cycles,
causing gene regulation rhythmicity. In mammals, the
suprachiasmatic nucleus (SCN) is the central clock regulated
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by light; it, in turn, synchronizes individual peripheral clocks
present in organs.14 Previous studies have demonstrated
that the retina has an independent circadian clock mediated
by photopigments, melanopsin, and dopamine.15 The reti-
nal clock regulates photoreceptor survival16 and ganglion
cell viability during aging,17 in addition to being critical for
retinal functions, such as phagocytosis, disk shedding, and
corneal thickness maintenance. AMPK, at the core of the
nutrient response, is known to phosphorylate and destabi-
lize core clock genes and alter circadian rhythm.18 Kir4.1
in Müller cells exhibits a diurnal rhythm, and disruption of
that rhythm dampens Kir4.1 expression, causing Müller cell
dysfunction.19 However, it remains unknown how the circa-
dian clock influences AMPK and Kir4.1 function.
The purpose of this study was to determine whether
AMPK activation by metformin, a common antidiabetic drug,
protects against Kir4.1 channel loss in Müller cells. Using
an animal model of type 2 diabetes (i.e., db/db mice), we
assessed wheel-running activity and studied the impact of
metformin on Kir4.1 expression in retinal Müller cells. This
animal model allowed us to investigate diabetes, circadian
rhythms, and retinal function under controlled conditions.
We observed that metformin treatment of diabetic mice
improved their wheel-running activity and corrected Kir4.1
levels in retinal Müller cells. Our study further reveals the
critical role of the clock gene Bmal-1 in modulating AMPK
signal and regulating Kir4.1 channels is Müller cells.
METHODS
Animals
The animal studies were performed according to the
National Institutes of Health Guiding Principles for the Care
and Use of Animals and the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research. The proto-
col was approved by the Institutional Animal Care and
Use Committee (IACUC) at Indiana University. Male, 10-
to 12-week-old BKS db (Leprdb/db) transgenic mice with a
C57BLKS/J genetic background and the control BKS db/m
(Leprdb/m) mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME, USA). The mice were housed in pairs
(for db/db mice, due to their weight) or four animals per
cage (for db/m mice) on a cob bedding. The bedding of the
diabetic mice was changed frequently due to polyuria. The
mice were maintained at normal room temperature under
a 12-hour light/12-hour dark cycle in the animal care facil-
ities of Indiana University. The welfare of the animals as
regularly assessed by the veterinary staff of the Laboratory
Animal Resource Center of Indiana University.
Locomotor Activity in Circadian Cabinets. The
wheel-running activity was determined in circadian cabinets
(Actimetrics, Wilmette, IL, USA). These cabinets are light
tight, filtered, and fully ventilated. The built-in connectors
were adapted to record temperature, humidity, light levels,
and locomotor activity. The Leprdb/db mice were randomly
divided into two groups. One group of mice received
metformin (164 mg/kg) through their drinking water for
14 days; the metformin was dissolved at a concentration of
0.5 mg/ml. The db/db mice, on average, drank ∼15 ml of
water (15.2 ± 3.3 ml), and their average weight was 46.08
± 7.8 g; therefore, the daily dose of metformin was 164 ±
40 mg/kg/day. The other groups received plain water. The
Leprdb/m mice served as controls, and their wheel-running
activity was recorded. Actimetrics ClockLab software was
used to analyze the diurnal rhythm.
Euthanasia of Mice. Per the IACUC protocol, the mice
were euthanized by CO2 intoxication at the same time in the
afternoon, between 1 PM and 2 PM. CO2 was delivered at an
acceptable low rate of 10 to 30% volume displacement per
minute.
Immunostaining
The retinal tissues were fixed onto slides with 4%
paraformaldehyde. The retinal sections were blocked in 2%
goat serum in staining buffer for 2 hours at room tempera-
ture. Primary antibodies—anti-Kir4.1 (1:200) anti-glutamine
synthetase 1 (GS-1) (1:200)—were incubated overnight at
4°C. The secondary antibody (Alexa Fluor 488 Goat Anti-
Rabbit and Alexa Fluor 555 Goat Anti-Mouse; Thermo
Fisher Scientific, Waltham, MA, USA) were incubated for
2 hours. VECTASHIELD Antifade Mounting Medium with
DAPI (Vector Laboratories, Burlingame, CA, USA) was added,
and a coverslip was placed and sealed with nail varnish.
Immunostained retinal sections were then observed under a
fluorescence microscope.
Cell Culturing of Rat Retinal Müller Cells
The rat retinal Müller cell line (rMC-1) was generously gifted
by Vijay Sarthy, Northwestern University, and Timothy S.
Kern, University of California, Irvine. The rMC-1 cells were
authenticated in series of tests: (1) short tandem repeat anal-
ysis, and (2) contamination of interspecies and mycoplasma
(IDEXX BioAnalytics, Columbia, MO, USA). The rMC-1 cells
were cultured in low-glucose (1000 mg/L) Dulbecco’s modi-
fied Eagle’s medium containing 10% fetal bovine serum,
1% antibiotic/antimycotic (100×), and 1% L-glutamine. rMC-
1 cells were seeded (2.1 × 106 cells per T75 flask) and
incubated overnight in media (vide supra) at 37°C to allow
attachment to the poly-D-lysine-coated surface. When 70%
confluency had been reached the following day, the cells
attached to the T75 flask were detached using trypsin-EDTA
(0.05%) and further cultured (vide supra) into T75 flasks at
a splitting ratio of 1:3. Each T75 flask was then transferred
into a six-well plate (0.3 × 106 cells/ well) and incubated
overnight for further in vitro studies.
Prkaa1 siRNA. The rMC-1 cells were transfected with
5-nM Prkaa1 siRNA or negative control silencer control
siRNA (Ambion; Life Technologies, Carlsbad, CA, USA) using
Invitrogen Lipofectamine RNAiMax Transfection Reagent
(Thermo Fisher Scientific) according to the manufacturer’s
instructions, and the cells were cultured for a further 24
hours.
AICAR and Metformin Treatment. The rMC-1 cells
were treated with 500-μM 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) or 1-mM metformin for 5, 15, and 30
minutes.
Protein Analysis via Western Blotting
Cells were lysed in 50 μl RIPA buffer (Thermo Fisher Scien-
tific) as per the manufacturer’s protocol. Protein concentra-
tions were estimated using the Pierce BCA Protein Assay
Kit (Thermo Fisher Scientific) and was read using a Synergy
H1 Hybrid Reader (BioTek Instruments, Winooski, VT, USA).
Equal amounts of proteins (30 μg) were loaded and sepa-
rated on 4% to 12% Novex Bis-Tris gel (Life Technologies).
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TABLE 1. Metabolic Parameters
Parameter, Mean ± SEM db/m Mice n db/db Mice n db/db + Met Mice n
Body mass (g) 32.61 ± 0.86 9 51.26 ± 3.71** 5 49.69 ± 3.07*** 8
Insulin (ng/ml) 0.77 ± 0.11 10 5.52 ± 2.48 7 4.25 ± 1.47 11
Glycated hemoglobin (%) 3.92 ± 0.13 9 8.13 ± 0.73** 7 7.98 ± 0.65*** 11
Brown–Forsythe and Welch ANOVA followed by unpaired t-test; **P < 0.01, ***P < 0.001 versus db/m.
FIGURE 1. Metformin corrects circadian rhythm in db/db mice. (A) Representative actograms show the wheel-running activity of db/m and
db/db mice under regular light and dark conditions. (B) Bar chart shows the total wheel-running activity of db/m mice (n = 61), db/db
mice (n = 42), and metformin-treated db/db mice (n = 55). ****P < 0.0001 (Brown–Forsythe and Welch ANOVA test followed by unpaired
t-test).
Proteins were transferred to a polyvinylidene difluoride
membrane, which was blocked with 4% BSA (Sigma-Aldrich,
St. Louis, MO, USA) in Tris-buffered saline and 0.1% Tween
20 (TBST; Sigma-Aldrich). Blocked membranes were then
incubated overnight at 4°C with primary antibodies: rabbit-
anti-Kir4.1 (1:2000), rabbit-anti-Bmal-1 (1:2000), and mouse-
anti-α-tubulin (1:5000). Following the overnight incubation,
membranes were incubated for 1 hour with secondary anti-
bodies: goat anti-rabbit IgG (H+L) horseradish peroxidase
(HRP) (1:2000) and goat anti-mouse IgG (H + L) HRP
(1:100) obtained from Thermo Fisher Scientific and Santa
Cruz Biotechnology (Dallas TX, USA). Following washing in
TBST, Pierce ECL plus western blotting substrate (Thermo
Fisher Scientific) was utilized to ensure adequate exposure
for detection. The bands were visualized using Typhoon FLA
9500 (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). The
images were then processed using ImageJ (National Insti-
tutes of Health, Bethesda, MA, USA). Each experiment was
repeated five times (biological replicates), and the western
blot intensities were represented in bar charts as integrated
optical density.
Statistical Analysis
The data values are expressed as the mean ± SEM of an
independent biological data point unless otherwise speci-
fied. Following are the number of mice in each group: db/m
(n = 12), db/db (n = 9), and db/db + metformin (n = 8).
The statistical significance was considered to be P < 0.05.
Results were compared using unpaired t-tests for two groups
or using either the Brown–Forsythe and Welch ANOVA test
followed by unpaired t-tests or the Kruskal–Wallis ANOVA
followed by a Dunn’s test for multiple comparisons, using
Prism 8.3.0 (GraphPad Software, La Jolla, CA, USA). The
details of the respective statistical tests are provided in the
figure legends.
Due to individual behavioral variation, the daily wheel-
running activity for each mouse from day 8 to day 14 (after
a washout period of 1 week) was used for statistical anal-
ysis. The sample size for wheel-running activity, therefore,
represents the number of mice in each group × 7 days. The
statistical analysis was performed using the Brown–Forsythe
and Welch ANOVA test followed by unpaired t-tests with
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TABLE 2. Activity Patterns
Revolutions/Day, Mean ± SEM db/m Mice n db/db Mice n db/db + Met Mice n
Total activity 21,303 ± 1305 61 632.1 ± 140*** 42 1322 ± 271# 55
Light activity 1207 ± 257 61 70.21 ± 14*** 42 339.4 ± 61### 55
Dark activity 20,096 ± 1273 61 562.1 ± 130**** 42 1285 ± 230### 55
For db/db compared to db/m, ***P < 0.001, ****P < 0.0001. For db/db compared to db/db + Met, ###P < 0.001, #P < 0.05.
FIGURE 2. Metformin treatment upregulates Kir4.1 channels in db/db mice. Retinal sections were stained with GS-1 (red) and Kir4.1 (green).
The db/db retinas demonstrated an overall decrease in Kir4.1 channels near the blood vessels (white arrows) and outer limiting membrane
(small arrow head). The metformin treatment corrected Kir4.1 levels in db/db mice (n = 9) near the blood vessels. Inset shows images at
higher magnification. Scale bar: 20 μm. GLC, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform
layer; ONL, outer nuclear layer; PR, photoreceptor layer.
Welch’s correction or the Dunnett T3 multiple comparison
test.
RESULTS
Metformin Treatment Corrects Wheel-Running
Activity in db/db Mice
Overall, the metformin treatment was well tolerated by
the mice, who showed no adverse effects. Metformin
had no effect on body mass, insulin levels, or glycated
hemoglobin (Table 1). The db/db mice are known to exhibit
a disturbed circadian rhythm. The assessment of wheel-
running activity using circadian rhythm cabinets helps in
the measurement of circadian rhythms. Using this tool, we
investigated whether or not metformin treatment would
correct circadian rhythm dysfunction in db/db mice. The
db/m mice exhibited a rhythmic pattern of wheel-running
consistent with the nocturnal nature of rodents—that is, an
increase in wheel running during the night (lights off) and
little to no wheel-running during the day (lights on). The
wheel-running of db/db mice was sporadic and showed no
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consistent pattern. The metformin treatment improved the
overall wheel-running, and there was an improvement in
the rhythmic pattern of wheel running (Fig. 1A).
Using ClockLab software, we performed a series of quan-
titative assessments of circadian parameters. Overall, the
metformin treatment improved total wheel-running activity,
as demonstrated by an increase in the number of revolutions
per day for the metformin-treated group (Fig. 1B). When
the activity pattern was further subdivided into light and
dark phase, there was an improvement in revolutions for
the metformin treatment for both phases (Table 2).
Metformin Treatment Corrects Kir4.1 in db/db
Mice
To determine the protective effect of metformin treatment
on retinal Kir4.1 level, we stained retinal sections from db/m
and db/db mice with Kir4.1 (green) to visualize the promi-
nence of inwardly-rectifying potassium channels and GS-1
(red) for the identification of Müller cells. The isotype control
for GS-1 did not exhibit non-specific staining (Supplemen-
tary Fig. S1). Kir4.1 staining of the retinal sections of db/m
mice near the blood vessels, internal limiting membrane,
and outer limiting membrane was consistent with previous
reports.7,20 The db/db mice demonstrated a decrease in both
Kir4.1 and GS-1 staining; however, there was no apparent
change in Müller cell numbers. There was an increase in
Kir4.1 staining in the metformin-treated db/db mice, around
the blood vessels, outer plexiform layer, and outer limiting
membrane (Fig. 2).
Metformin Treatment Corrects the Retinal Clock
In order to gain insight into the involvement of the reti-
nal clock in correcting the overall rhythm of db/db mice,
we studied mRNA levels of three key components of the
retinal clock: arylalkylamine N-acetyltransferase (AANAT),
melanopsin (Opn4), and tyrosine hydroxylase (Th). The
db/db mice showed a significant decrease in AANAT (Fig. 3A)
and Opn4 (Fig. 3B); however, a decrease observed in Th did
not reach statistical significance (Fig. 3C). The metformin
treatment significantly corrected the lower levels of AANAT
and Opn4, and the levels of Th in db/db mice remained
unchanged. (Figs. 3A–3C).
Metformin Treatment Regulates Kir4.1 via AMPK
Metformin indirectly mediates AMPK phosphorylation
through inhibition of complex 1 of the mitochondrial respi-
ratory chain, which leads to an increased AMP:ATP ratio.21,22
To test whether metformin has an effect on Müller cells, we
treated rMC-1 cells with metformin in vitro. We performed
a time–response study of 5 to 30 minutes. We detected
a significant increase in Kir4.1 protein expression at 15
minutes (Figs. 4A, 4B). Next, we used a specific activator
of AMPK, AICAR, to determine whether the Kir4.1 increase
is AMPK dependent. We treated rMC-1 cells with AICAR
in vitro and performed a time–response study of 5 to 30
minutes. An increase in Kir4.1 was observed at all time
points, but we observed a significant increase in Kir4.1
protein expression at 15 minutes, similar to the effect of
metformin (Figs. 4C, 4D) as compared to the untreated
control. To further establish the role of AMPK in regulating
Kir4.1, we performed a loss-of-function study using siRNA
FIGURE 3. Metformin treatment corrects retinal clock. Bar chart
shows mRNA levels of (A) arylalkylamine N-acetyltransferase
(AANAT), (B) melanopsin 4 (Opn-4), and (C) tyrosine hydroxylase
(Th) after treatment with metformin (db/m mice, n = 12; db/db
mice, n = 9; db/db + metformin mice, n = 8). *P < 0.05, **P <
0.01 (Brown–Forsythe and Welch ANOVA test followed by unpaired
t-test).
for AMPK (Prkaa1). The AMPK siRNA successfully reduced
Prkaa1 mRNA levels (Fig. 4E). We treated the rMC-1 cells
with Prkaa1 siRNA and evaluated the protein expression
of Kir4.1. Transfection of rMC-1 cells with Prkaa1 siRNA
substantially decreased Kir4.1 protein levels (Figs. 4F, 4G)
Clock Gene Bmal-1 Is a Mediator of Kir4.1
To understand the relevance of circadian rhythm to AMPK
and Kir4.1, we sought to study the circadian clock gene,
Bmal-1. We have previously reported that the expression
of Kir4.1 in Müller cells is under clock regulation through
the Bmal-1 gene.19 To test whether AMPK activation influ-
ences Bmal-1 levels, we treated rMC-1 cells with metformin
and AICAR, and the protein expression of Bmal-1 was eval-
uated. With the metformin treatment (Figs. 5A, 5B), there
was a significant increase in Bmal-1 at 15 minutes, and for
the AICAR treatment (Figs. 5C, 5D) there was a significant
increase in Bmal-1 at all time points. To further understand
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FIGURE 4. AMPK regulates Kir4.1 in rat Müller cells. The cultured
rMC-1 cells were treated with metformin, AICAR, or vehicle (UT,
untreated) at different time intervals. The western blots show an
increase in Kir4.1 levels in rMC-1 cells treated with (A) metformin
and (C) AICAR. The bar charts show integrated optical density data
for (B) metformin and (D) AICAR treatment (n = 5; *P < 0.05).
The rMC-1 cells were transfected with AMPKα1 (Prkaa1) siRNA or
a scrambled control siRNA. (E) Bar chart shows mRNA levels of
Prkaa1 after siRNA silencing (n = 6; **P < 0.01, unpaired t-test).
A representative western blot (F) and its respective bar chart (G)
show a decrease in Kir4.1 protein expression when AMPK (Prkaa1)
is silenced (n = 5; *P < 0.05, Kruskal–Wallis ANOVA followed by
Dunn’s test).
the influence of AMPK on Bmal-1, we silenced AMPK in rMC-
1 cells with Prkaa1 siRNA, and Bmal-1 protein expression
was assessed. Prkaa1 siRNA transfection decreased Bmal-1
protein expression (Figs. 5E, 5F).
Metformin Treatment of db/db Mice Upregulates
Kir4.1 via AMPK and Bmal-1
Next, we tested the hypothesis that AMPK–Bmal-1 activa-
tion has a protective effect on Kir4.1 levels in db/db mice.
We analyzed the protein expression of AMPK and Kir4.1,
as well as the phosphorylation of AMPK-α1, on threonine
172. The db/db mice showed a decrease in total AMPK, and
there was a decrease in phosphorylated AMPK-α1 (Fig. 6A).
The protein levels of Bmal-1 (Fig. 6B) and Kir4.1 (Fig. 6C)
were decreased in db/db mice, and the metformin treatment
corrected the reduced levels of these proteins in db/db mice.
DISCUSSION
We previously found that DR is associated with dysregu-
lated diurnal rhythm.23 Diabetes causes damage to retinal
potassium conductance, resulting in a drastic decrease in
Kir4.1 expression.6,7 It has also been found that the induc-
tion of diabetes inactivates AMPK in the retina.24 AMPK
activity is a crucial element of the central clock in the
suprachiasmatic nucleus, as it produces a regulatory circa-
dian rhythm response for the metabolic system and gene
expression.25 Aligning with these studies, we observed that
metformin treatment of db/db mice corrects the central
circadian rhythm, modifying the target retinal clock genes
and Kir4.1 channel.
The db/db mice that received metformin exhibited nearly
equivalent body weight and glycated hemoglobin and
insulin levels at the study termination. We did not see an
expected change in glycated hemoglobin after metformin
treatment. We believe this may be attributed to the shorter
duration of this study; typically, a change in glycated
hemoglobin is observed 2 to 3 months after initiation of
metformin treatment. It is noteworthy that the changes that
we observed in our study cannot be attributed to a systemic
decrease in blood glucose but rather are due to the non-
glucose-mediated effects of metformin.
Retinal neurodegeneration is recognized to be an initial
pathway involved in the pathogenesis of DR, contribut-
ing to microcirculatory events that arise as part of DR.26
Müller cells are principal glial cells of the retina and are
central, columnar “micro units” of retinal neurons.6 A char-
acteristic of mature Müller cells is their strong potassium
conductance, and Kir4.1 is a predominant potassium chan-
nel that is involved in correcting potassium concentrations
due to its polarized arrangement in Müller cells.8,27 In our
studies, metformin treatment improved Kir4.1 levels near the
blood vessels and outer limiting membrane; strikingly, Kir4.1
levels on the internal limiting membrane decreased, support-
ing the possibility of delocalization or altered distribution of
Kir4.1 channels reported previously.20
Metformin, a widely prescribed type 2 diabetes drug,
promotes skeletal muscle glucose uptake.28,29 Metformin is
known to activate AMPK in an indirect manner via inhibition
of mitochondrial complex I. AMPK is required for its lipid-
lowering and insulin-sensitizing action. Because the inter-
action between AMPK and Kir4.1 potassium conductance is
crucial to osmotic balance, we aimed to observe the interac-
tive roles of AMPK and Kir4.1. Previous studies have associ-
ated Müller cell swelling with the induction of osmotic stress.
A decrease in potassium conductance is related to the down-
regulation of both gene and protein expression of Kir4.1.30
AMPK, especially AMPKα1, has been known to be activated
under osmotic stress conditions.31 AICAR is a cell-permeable
precursor that phosphorylates to imidazole monophosphate,
mimicking AMP, which directly acts as an agonist for AMPK
activation.28,32 The induction of AICAR confirms the collab-
orative role of AMPK and Kir4.1. We observed that Kir4.1
protein expression increased when AMPK was activated
through its agonist, AICAR, suggesting that AMPK plays a
protective role in the pathogenesis of DR.28
We found that the activation of AMPK by metformin
resulted in a significant increase in Kir4.1 protein
expression, providing evidence for the correlation of AMPK
and Kir4.1 in the maintenance of Müller cells. In contrast,
Prkaa1 siRNA silences AMPK and reduces Kir4.1 expres-
sion, confirming the connection between Kir4.1 and AMPK.
In a previous study, mouse embryonic fibroblast cells were
cultured in normal glucose and treated with AICAR. The
circadian period was lengthened compared to the standard
(low) glucose medium.33 It would have been interesting to
study similar culturing conditions for rMC-1 cells; however,
we were primarily interested in establishing the effect of
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FIGURE 5. The clock gene Bmal-1 is an important regulator of AMPK in Müller cells. rMC-1 cells were treated with metformin, AICAR, or
vehicle (UT, untreated), and the Bmal-1 levels were determined using western blots. The representative images of western blots and bar
charts show upregulation of Bmal-1 after treatment with (A, B) metformin (n = 4) or (C, D) AICAR (n = 5; *P < 0.05, Kruskal–Wallis ANOVA
followed by Dunn’s test). (E) AMPKα1 siRNA-transfected rMC-1 cells show a decrease in Bmal-1. (F) The bar chart shows the quantification
of integrated optical density (n = 5).
AMPK activation under standard glucose conditions, so our
studies were limited to low-glucose conditions.
Circadian rhythms are synchronized to the 24-hour
period of the Earth’s rotation, and light serves as the major
synchronizing agent.34 Diabetes is linked with circadian
rhythm disruption of the central and peripheral circadian
clock, and it disrupts the circadian regulation of core clock
genes occurring in the retina. The retina is an extremely
cyclic tissue, with metabolic and inflammatory demands fluc-
tuating considerably due to the influence of light and dark
cycles. Altered synchronization in association with retinal
demands in diabetes could attribute to DR pathogenesis.14
In our study, we detected the diminishing effect of Kir4.1
specific to Müller cells in diabetic mice; however, it is known
that db/db mice are leptin receptor resistant and are known
to possess circadian rhythm dysfunction. Leptin plays a vital
role in the signaling properties of the brain that control
energy and metabolism.35 Therefore, it is likely that the
protective effect of metformin may have a central mecha-
nism involving leptin signaling, which was not investigated
here but our study paves the way for future studies in this
direction.
The circadian rhythm mechanism is closely regulated
to the interlinked expression of specific clock regulatory
genes.36 Binding of the CLOCK:Bmal-1 unit to the E-boxes
of CRY and PER activates Cry and Per promoters, respec-
tively, causing CRY and PER protein translation during the
late hours of the day and early hours of the night.37 CRY
and PER complex bind to the CLOCK:Bmal-1 unit, creating
a negative feedback loop and inhibiting its own transcrip-
tion of Cry and Per mRNA. AANAT stability is regulated by
cAMP, and its transcription is controlled directly by the circa-
dian clock via the presence of an E-box in the promoter
region.38 We previously reported that the Kncj10 promoter
gene for Kir4.1 exhibits an E-box, and Bmal may serve as a
regulator of Kir4.1 protein expression.19,38 It is noteworthy
that, in our studies, metformin treatment upregulated gene
expression for melanopsin mRNA, opn4. The melanopsin
is expressed by intrinsically photosensitive retinal ganglion
cells; these non-image-forming photoreceptor cells commu-
nicate directly with the SCN, as well as with other areas of
brain cells.39 Although dopamine has been reported to play
an important role in regulating the retinal clock, we did not
see a beneficial effect of metformin on tyrosine hydroxy-
lase.40 Thus, in our studies, we speculate that metformin
treatment produced a physiologically significant effect by
increasing Kir4.1 via the AMPK–Bmal pathway and correct-
ing the retinal clock and overall daily rhythm in db/db mice.
However, long-term studies are necessary to establish causal
relationships with the development of DR.
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FIGURE 6. Metformin treatment of db/db mice upregulates Kir4.1
via AMPK. Representative western blots show the protein expres-
sion and the respective bar charts show the quantification of the
following: (A) PhosphoAMPKt172 and total AMPK (control mice,
n = 6; db/db mice, n = 6; db/db + Met mice, n = 5; *P <
0.05, Kruskal–Wallis ANOVA followed by Dunn’s test). (B) Bmal-
1 (control mice, n = 4; db/db mice, n = 4; db/db + Met mice, n =
4; *P < 0.05, **P < 0.01, Kruskal–Wallis ANOVA followed by Dunn’s
test). (C) Kir4.1 in metformin-treated db/db mice (control mice, n =
8; db/db mice, n = 8; db/db + Met mice, n = 5; *P < 0.05, Kruskal–
Wallis ANOVA followed by Dunn’s test).
Despite these limitations, our studies suggest that
metformin treatment is protective for the principal inwardly
rectifying potassium-conducting channel, Kir4.1, in Müller
cells. When AMPK is mediated through AICAR and
metformin, Kir4.1 protein expression is increased, with
Bmal-1 playing an intermediary role. Our results suggest that
AMPK is a crucial therapeutic target in preventing Müller cell
dysfunctionality in DR.
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